Rhabdomyolysis following cerivastatin monotherapy - Implications for therapy with HMG-CoA reductase inhibitors;Rhabdomyolyse unter cerivastatin-monotherapie: Konsequenzen für die therapie mit HMG-CoA-reduktase-hemmern?

Nervenarzt

Volumn 74, Issue 2, 2003, Pages 167-171

  Sparing, R ^a   Sellhaus, B ^a   Noth, J ^a   Block, F ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

HMG CoA reductase inhibitors; LDL cholesterol; Myopathy; Rhabdomyolysis; Statines

Indexed keywords

ALLOPURINOL; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; CALCIUM ANTAGONIST; CERIVASTATIN; CLOZAPINE; COLESTYRAMINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; FLUVOXAMINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; MACROLIDE; NEFAZODONE; PROPRANOLOL; PROTEINASE INHIBITOR; RITONAVIR; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; DRUG METABOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MUSCLE BIOPSY; RHABDOMYOLYSIS;

ACUTE DISEASE; ANTICHOLESTEREMIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOPSY; COMORBIDITY; CREATINE KINASE; CYTOCHROME P-450 ENZYME SYSTEM; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; ELECTROMYOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; MIDDLE AGED; MUSCLE, SKELETAL; NEUROLOGIC EXAMINATION; PANCREATIC DISEASES; PYRIDINES; RHABDOMYOLYSIS; STOMACH NEOPLASMS; UBIQUINONE;

EID: 0038813961     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-002-1441-x     Document Type: Article

References (29)

1. Arzneimittelkommission derdeutschen Ärzteschaft (2002) Rhabdomyolyse unter einer Therapie mit Statinen. Dt Ärzteblatt 99:C508
2. Beetham R (2000) Biochemical investigation of suspected rhabdomyolysis. Ann Clin Biochem 37:581-587
3. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD (2000) Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 57:461-464
4. Bischoll H, Heller A (1998) Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol 82 [Suppl 4B]:18
5. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428
6. Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81:368-369
7. Endres M, Laufs U (1998) HMG-CoA reductase inhibitor and risk of stroke. Nervenarzt 69:717-721
8. Farmer JA (2001) Learning from the cerivastatin experience. Lancet 358:1383-1385
9. Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205-207
10. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH (2002) Statins and risk of polyneuropathy: a case-control study. Neurology 58:1333-1337
11. Hanefeld M, Patzak A, Schaper F, Temelkova-Kurktschiev T (1999) Klinische Pharmakologie der Statine. In: Hanefeld M (ed) Statine. Uni-Med, Bremen, pp 76-104
12. Hargreaves IP, Heales S (2002) Statins and myopathy, Lancet 359:711-712
13. Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 128:159-168
14. Lucas RA, Weathersby BB, Rocco VK, Pepper JM, Butler KL (2002) Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy 22:771-774
15. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207-213
16. Milionis HJ, Tsapoga TG, Elisaf MS (2001) Another report of acute rhabdomyolysis following cerivastatin monotherapy. Arch Intern Med. 161:2629-2630
17. Omar MA, Wilson JP, Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107
18. Omar MA, Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 36:288-295
19. Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264:71-75
20. Pogson GW, Kindred LH, Carper BG (1999) Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 83:1146
21. Ravnan SL, Locke C, Yee WP, Haase K (2002) Cerivastatin-induced rhabdomyolysis: 11 case reports. Pharmacotherapy 22:533-537
22. Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ Jr, Green M, Andrews LG, Faich GA (1990) Physician reporting of adverse drug reactions. JAMA 263:1785-1788
23. Shek A, Ferrill MJ (2001) Statin-fibrate combination therapy. Ann Pharmacother 35:908-917
24. Sica DA, Gehr TW (2002) Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 11:48-55
25. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540
26. Vanholder R, Sever MS, Erek E, Lameire N (2000) Rhabdomyolysis. J Am Soc Nephrol 11:1553-1561
27. Vera M, Pou M, Botey A, Cases A (2001) Massive rhabdomyolysis associated with the use of cerivastatin monotherapy. Nefrologia 21:613-614
28. Visweswaran P, Guntupalli J.(1999) Rhab domyolysis. Crit Care Clin 15:415-428
29. Weaver SJ, Doering PL (2002) Cerivastatin and the dissemination of adverse event information. Ann Pharmacother 36:1099-1103